A Randomized, Double-Masked, Single-Center, Placebo-Controlled Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of SJP-0132 in Subjects With Dry Eye Disease
Sponsor study identifier
interventional
89
1 country
1
Study Start
October 5, 2019
Actual (reported)Primary Completion
March 3, 2020
Actual (reported)Study Completion
March 3, 2020
Actual (reported)This is the first study in humans to evaluate the effectiveness of SJP-0132 in the treatment of dry eye disease. This study will evaluate the safety, tolerability, efficacy, and pharmacokinetics of single- and multiple-dose regimens of SJP-0132 in subjects with dry eye disease
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 3, 2020
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 5, 2019
Actual (reported)October 14, 2019
Actual (reported)October 25, 2019
Actual (reported)March 3, 2020
Actual (reported)March 3, 2020
Actual (reported)April 20, 2023
Actual (reported)Number of Participants With Adverse Events by Severity in Each Cohort
Number of participants with adverse events by severity are summarize in each cohort. Adverse events are reported as Treatment-Emergent Adverse Events (TEAEs), which are defined as any event not present before exposure to the study drug or any event already presented that worsened in either intensity or frequency after exposure to the study drug.
Day 2 for cohort 1-4, Day 29 for cohort 5-6
Number of Subjects With Abnormal Changes in Laboratory Parameters, Vital Signs, and/or Physical and Ophthalmologic Observations in Each Cohort
Clinical laboratory parameters include hematology, clinical chemistry, urinalysis, and serology. Vital signs include diastolic blood pressure, systolic blood pressure, heart rate, respiratory rate, and body temperature. Ophthalmologic observations include examination of visual acuity, slit lamp biomicroscopy, Schirmer I, intraocular pressure, and ophthalmoscopy.
Day 2 for cohort 1-4, Day 29 for cohort 5-6
Maximum Plasma Concentration (Cmax)
The results are from the maximum plasma concentration (Cmax) on Day 1. The blood for pharmacokinetics assessment was collected at 0, 0.25, 0.5, 1, 2, 4, 8, and 12 hours after dosing on Day 1 for Cohorts 1 to 4. The blood for pharmacokinetics assessment was collected at 0, 0.25, 0.5, 1, 2, and 4 hours after dosing on Day 1 for Cohorts 5 and 6.
Day 1
Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUC0-last)
Change From Baseline in Eye Dryness Symptom by Visual Analog Scale (VAS) in Each Timepoints
Day 29
Change From Baseline in Corneal Fluorescein Staining (CFS) Score at Total Zone in Each Timepoints
Day 8, 15, 22, 29
Change From Baseline in Conjunctival Lissamine Green Staining (CLGS) Score at Total Zone in Each Timepoints
Day 8, 15, 22, 29
Change From Baseline in Lid Wiper Epitheliopathy Score in Each Timepoints
Day 8, 15, 22, 29
Change From Baseline in Tear Film Break-up Time (TFBUT) in Each Timepoints
Day 8, 15, 22, 29
Each cohort will receive a single dose of 1 of 4 strengths of SJP-0132
Single dose of placebo
Cohort 5 SJP-0132 will receive the second maximum acceptable dose from Cohorts 1-4 for 4 weeks. Cohort 6 SJP-0132 will receive the maximum acceptable dose from Cohorts 1-4 for 4 weeks
SJP-0132 is administered as an eye drop
Placebo is administered as an eye drop
Senju Investigational Site
Cypress, California, 90630, United States
All of the efficacy and safety measurements applied in this study are widely used and generally recognized as reliable, accurate, and relevant.
89 participants (actual enrollment reported by the registry).
First Submitted
October 14, 2019
First Posted
October 25, 2019
Study Start
October 5, 2019
Actual (reported)Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
Area under the plasma concentration-time curves (AUCs) for Cohorts 1 to 4 were calculated using the plasma collected at 0, 0.25, 0.5, 1, 2, 4, 8, and 12 hours after dosing on Day 1, and those for Cohorts 5 and 6 were calculated using the plasma collected at 0, 0.25, 0.5, 1, 2, and 4 hours after dosing on Day 1.
Day 1
Accumulation Ratio (Rac) After Multiple Dosing
Plasma were collected at 0, 0.25, 0.5, 1, 2, and 4 hours after dosing on Day 1, pre-dose on Day 2, Day 4 and Day 8. Accumulation ratios calculated as (predose plasma concentration \[Ctrough\] on Day 4) / (Ctrough on Day 2) and (Ctrough on Day 8) / (Ctrough on Day 2)
Day 2, 4, 8
Change From Baseline in Eye Dryness Symptom (VAS) at 4hour on Day 29
Visual analog scale (VAS): "0" mean none, and "100" mean the worst imaginable for the symptom question.
Day 29
Change From Baseline in Corneal Fluorescein Staining (CFS) Score at the Central Zone on Day 29
Change from baseline of central zone CFS score at the central zone on Day 29. CFS score at the central zone ranged from 0 to 5, where '0' represents no fluorescein staining, and '5' represents severe staining on the cornea. The higher scores mean worse outcomes. Results from the study eye are reported.
Day 29
Multiple dose placebo for 4 weeks
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
March 3, 2020
Actual (reported)Study Completion
March 3, 2020
Actual (reported)Last Updated
April 20, 2023
Results First Posted
April 20, 2023
Record last verified: 2023-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: